09:52 AM EST - Adherex Technologies Inc. : announced that the FDA's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee will discuss the development of Sodium Thiosulfate Injection, USP, 25% (STS) on November 1. STS is a chemoprotectant being developed to reduce or prevent hearing loss in children that can result from treatments utilizing platinum-based chemotherapy drugs. Adherex Technologies Inc.
shares T.AHX are trading even at $0.60.
